The BMJ characterized Canada as only the second country in the world to approve a generic form of semaglutide, a step it linked to Novo Nordisk not paying a C$250 annual fee
Phase 3 trials (the TRIUMPH programme, registered on ClinicalTrials.gov) are currently underway, evaluating retatrutide across broader populations including those with cardiovascular disease, type 2 diabetes, and obesity-related complications
Check them with Symplicured before it escalates.
GLP-1 eligibility standards vary based on your health history, symptoms, and medical goals
Yang F, Luo X, Li J, Lei Y, Zeng F, Huang X, Lan Y, Liu R
Appetite can rebound strongly as the body resists losing fat